Keele Research Repository

Article

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, JS, Kirby, AM, Somaiah, N, Wheatley, DA, Bliss, JM and Yarnold, JR (2021) Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation. Clinical Oncology.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, JS, Wheatley, DA and Yarnold, JR (2020) Breast cancer radiation therapy - Authors' reply. Lancet, 396 (10262). 1559 - 1560.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, CE, Emson, M, Goodman, A, Harnett, A, Hopwood, P, Kirby, AM, Kirwan, C, Morris, C, Nabi, Z, Sawyer, E, Somaiah, N, Stones, L, Syndikus, I, Wilcox, M, Bliss, JM and Yarnold, JR (2020) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results. Radiotherapy and Oncology, 152 (S1). S346 - S347.

Brunt, AM, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, DJ, Chan, C, Churn, M, Cleator, S, Coles, CE, Goodman, A, Harnett, A, Hopwood, P, Kirby, AM, Kirwan, CC, Morris, C, Nabi, Z, Sawyer, E, Somaiah, N, Stones, L, Syndikus, I, Bliss, JM, Yarnold, JR and FAST-Forward Trial Management Group, . (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet, 395 (10237). 1613 - 1626.

Coles, CE, Griffin, CL, Kirby, AM, Titley, J, Agrawal, RK, Alhasso, A, Bhattacharya, IS, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Ciurlionis, L, Chan, C, Donovan, EM, Emson, MA, Harnett, AN, Haviland, JS, Hopwood, P, Jefford, ML, Kaggwa, R, Sawyer, EJ, Syndikus, I, Tsang, YM, Wheatley, DA, Wilcox, M, Yarnold, JR, Bliss, JM and Trialists, IMPORT (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet, 390 (10099). 1048 - 1060.